Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users
- 3 February 2017
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 37 (6) , 897-904
Abstract
Medication adherence is believed to be a major contributor to treatment outcomes yet studies quantifying this relationship as rare in rheumatoid arthritis (RA). To determine the association of adherence to DMARD therapy with treatment outcomes among new and existing DMARD users over 2 years. Relevant clinical parameters were obtained from a longitudinal cohort of RA patients, most of who were treated with combination therapy. Patients were classified as adherent if the proportion of days covered for each DMARD was ≥80%. Outcome measures were the change in the disease activity score in 28 joints (DAS28), simplified disease activity index (SDAI), modified health assessment questionnaires (mHAQ) and proportion of patients who achieved response criteria. An inverse propensity-score weighting method was used to estimate the association of adherence with each outcome. Of 194 patients invited, a total of 111 patients (new = 45 and existing = 66 DMARD users) met study eligibility. DMARD-naive patients demonstrated relatively higher rates of adherence compared to existing users. After controlling for confounding variables, adherence was significantly associated with reduction in DAS28 (β = −1.5, 95% CI of β = − 2.17 to −0.83, p < 0.0001), SDAI (β = −9.44, 95% CI of β = −15.53 to −3.35, p = 0.002) and mHAQ (β = −0.269, 95% CI of β, −0.462 to −0.077, p = 0.017) over 2 years among new patients and adherent patients were more likely to achieve most response criteria compared to non-adherent patients. Such associations were not replicated among existing DMARD users. Adherence to combination DMARD therapy was associated with improvements in disease activity and functional outcomes in the first 2 years of therapy.Keywords
This publication has 28 references indexed in Scilit:
- Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?International Journal Of Clinical Practice, 2016
- Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH)PLOS ONE, 2015
- Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohortRheumatology, 2014
- Distinct Trajectories of Disease Activity Over the First Year in Early Rheumatoid Arthritis Patients Following a Treat‐to‐Target StrategyArthritis Care & Research, 2013
- Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic ReviewClinical Therapeutics, 2011
- Patient Medication Adherence: Measures in Daily PracticeOman Medical Journal, 2011
- Estimating the Effect of Medication Adherence on Health Outcomes among Patients with Type 2 Diabetes—An Application of Marginal Structural ModelsValue in Health, 2010
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rateAnnals of the Rheumatic Diseases, 2009
- Response-Driven Combination Therapy with Conventional Disease-Modifying Antirheumatic Drugs Can Achieve High Response Rates in Early Rheumatoid Arthritis with Minimal Glucocorticoid and Nonsteroidal Anti-Inflammatory Drug UseSeminars in Arthritis and Rheumatism, 2007
- A simplified disease activity index for rheumatoid arthritis for use in clinical practiceRheumatology, 2003